<scp>MD</scp>‐2 as the target of a novel small molecule, <scp>L6H</scp>21, in the attenuation of <scp>LPS</scp>‐induced inflammatory response and sepsis

Abstract

Overall, this work demonstrated that the new chalcone derivative, L6H21, is a potential candidate for the treatment of sepsis. More importantly, the data confirmed that MD-2 is an important therapeutic target for inflammatory disorders.